Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,897 signal articles · 194 in last 24h · 157,635 total before filter · latest 2h ago
194last 24h
871last 7d
140● bullish (7d)
81● bearish (7d)
214publishers
AllMacro198Earnings142M&A102Regulatory18Product18Analyst24
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Investing.com61d agobearish
AT&T and Verizon tumble as Musk’s SpaceX plots direct mobile threat

AT&T, Verizon, and T-Mobile took a beating on Wednesday as investors braced for an orbital clash with Elon Musk. Shares of AT&T (NYSE: T) and Verizon (NYSE: VZ) both fell 4%, while T-Mobile (NASDAQ: TMUS) slid 2%, following a Semafor report that SpaceX is plotting a direct assault on the U.S. wireless oligopoly. The rocket titan is actively hunting urban-grade spectrum—either by snapping up rivals or crashing next year’s federal auction—to build out dense coverage in major cities. The selloff hi

Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
Investor's Business Daily61d agobearish
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results. Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition. The profit came in below the consensus estimate of 5 cents a share.

Morgan Stanley resets Akamai stock price target amid sell-off
TheStreet61d agobearish
Morgan Stanley resets Akamai stock price target amid sell-off

Wall Street is watching Akamai Technologies closely after a blockbuster deal reshaped the company's growth story earlier this year. Morgan Stanley reaffirmed its “Overweight” rating on Akamai (AKAM) in a July 27 research note shared with me, keeping its price target at $165, roughly 48% above the ...